Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025
Elite Pharmaceuticals (OTCQB:ELTP), a specialty pharmaceutical company focused on niche generic products, will release its Q1 FY2026 financial results on Thursday, August 14, 2025. The company will host a conference call on Friday, August 15, 2025, at 11:30 AM EDT to discuss financial results and provide a business update.
Shareholders can submit general questions by August 13, 2025 (5:00 PM EDT) and financial questions by August 14, 2025 (7:00 PM EDT) to [email protected]. The call will be accessible via 1-800-346-7359 (domestic) or 1-973-528-0008 (international) using conference number 98840. An audio replay will be available on the company's website.
Elite Pharmaceuticals (OTCQB:ELTP), una societ脿 farmaceutica specializzata in prodotti generici di nicchia, pubblicher脿 i risultati finanziari del primo trimestre dell'esercizio 2026 gioved矛 14 agosto 2025. La societ脿 terr脿 una conference call venerd矛 15 agosto 2025 alle 11:30 EDT per commentare i risultati e fornire un aggiornamento sull'attivit脿.
Gli azionisti possono inviare domande generali entro il 13 agosto 2025 (ore 17:00 EDT) e domande di natura finanziaria entro il 14 agosto 2025 (ore 19:00 EDT) a [email protected]. La chiamata sar脿 accessibile al numero 1-800-346-7359 (nazionale) o 1-973-528-0008 (internazionale) utilizzando il codice conference 98840. Una registrazione audio sar脿 disponibile sul sito web della societ脿.
Elite Pharmaceuticals (OTCQB:ELTP), compa帽铆a farmac茅utica especializada en gen茅ricos de nicho, publicar谩 sus resultados financieros del 1T del ejercicio 2026 el jueves 14 de agosto de 2025. La empresa celebrar谩 una conferencia telef贸nica el viernes 15 de agosto de 2025 a las 11:30 AM EDT para comentar los resultados y ofrecer una actualizaci贸n sobre el negocio.
Los accionistas pueden enviar preguntas generales hasta el 13 de agosto de 2025 (5:00 PM EDT) y preguntas financieras hasta el 14 de agosto de 2025 (7:00 PM EDT) a [email protected]. La llamada podr谩 seguirse marcando 1-800-346-7359 (dom茅stico) o 1-973-528-0008 (internacional) con el n煤mero de conferencia 98840. Habr谩 una grabaci贸n de audio disponible en la web de la compa帽铆a.
Elite Pharmaceuticals (OTCQB:ELTP)電� 雼堨箻 鞝滊劋毽� 鞝滍拡鞚� 鞝勲鞙茧 頃橂姅 鞝勲 鞝滌暯靷, 2026 須岅硠鞐半弰 1攵勱赴 鞁れ爜鞚� 2025雲� 8鞗� 14鞚� 氇╈殧鞚检棎 氚滍憸頃╇媹雼�. 須岇偓電� 鞛 瓴瓣臣 氚� 靷梾 鞐呺嵃鞚错姼毳� 瓿奠湢頃橁赴 鞙勴暣 2025雲� 8鞗� 15鞚� 旮堨殧鞚� 鞓れ爠 11鞁� 30攵�(EDT)鞐� 旎嵓霟办姢 旖滌潉 臧滌禍頃╇媹雼�.
欤检＜霌れ潃 鞚茧皹 歆堧鞚� 2025雲� 8鞗� 13鞚�(鞓ろ泟 5鞁� EDT)旯岇, 鞛 甏�霠� 歆堧鞚� 2025雲� 8鞗� 14鞚�(鞓ろ泟 7鞁� EDT)旯岇 [email protected]鞙茧 鞝滌稖頃� 靾� 鞛堨姷雼堧嫟. 旖滌潃 甑偞 1-800-346-7359 霕愲姅 頃挫櫢 1-973-528-0008 氩堩樃搿� 鞝戩啀頃橃棳 旎嵓霟办姢 氩堩樃 98840鞚� 靷毄頃橂┐ 霌れ潉 靾� 鞛堨姷雼堧嫟. 鞓る敂鞓� 鞛儩鞚� 須岇偓 鞗轨偓鞚错姼鞐愳劀 鞝滉车霅╇媹雼�.
Elite Pharmaceuticals (OTCQB:ELTP), une soci茅t茅 pharmaceutique sp茅cialis茅e dans les g茅n茅riques de niche, publiera ses r茅sultats financiers du 1er trimestre de l'exercice 2026 le jeudi 14 ao没t 2025. La soci茅t茅 tiendra une conf茅rence t茅l茅phonique le vendredi 15 ao没t 2025 脿 11h30 (EDT) pour commenter les r茅sultats et faire le point sur l'activit茅.
Les actionnaires peuvent envoyer des questions g茅n茅rales jusqu'au 13 ao没t 2025 (17h00 EDT) et des questions financi猫res jusqu'au 14 ao没t 2025 (19h00 EDT) 脿 [email protected]. L'appel sera accessible au 1-800-346-7359 (num茅ro national) ou au 1-973-528-0008 (international) en utilisant le num茅ro de conf茅rence 98840. Une rediffusion audio sera disponible sur le site web de la soci茅t茅.
Elite Pharmaceuticals (OTCQB:ELTP), ein auf Nischen-Generika spezialisiertes Pharmaunternehmen, wird seine Finanzergebnisse f眉r das erste Quartal des Gesch盲ftsjahrs 2026 am Donnerstag, 14. August 2025, ver枚ffentlichen. Das Unternehmen wird am Freitag, 15. August 2025, um 11:30 Uhr EDT eine Telefonkonferenz abhalten, um die Ergebnisse zu erl盲utern und ein Gesch盲ftsupdate zu geben.
Aktion盲re k枚nnen allgemeine Fragen bis zum 13. August 2025 (17:00 Uhr EDT) und finanzielle Fragen bis zum 14. August 2025 (19:00 Uhr EDT) an [email protected] senden. Die Teilnahme ist 眉ber 1-800-346-7359 (inl盲ndisch) oder 1-973-528-0008 (international) mit der Konferenznummer 98840 m枚glich. Eine Audioaufzeichnung wird auf der Unternehmenswebsite verf眉gbar sein.
- None.
- None.
Financials for First Quarter of Fiscal Year 2026 Ended June 30, 2025 will be released on Thursday, August 14, 2025
Northvale, New Jersey--(Newsfile Corp. - August 8, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2026 fiscal year will be released on Thursday, August 14, 2025. Elite's management will host a live conference call on Friday, August 15th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. Stockholders should submit their questions to the company prior to the call.
| Date: | August 15, 2025 |
| Time: | 11:30 AM EDT |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | [email protected] General questions by 5:00 PM EDT on Wednesday, August 13, 2025 Financial questions by 7:00 PM EDT on Thursday, August 14, 2025 |
| Audio Replay: |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit .
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
[email protected]
To view the source version of this press release, please visit
FAQ
When will Elite Pharmaceuticals (ELTP) release Q1 2026 earnings?
What time is Elite Pharmaceuticals' Q1 2026 earnings call?
How can investors submit questions for Elite Pharmaceuticals' Q1 2026 earnings call?
What are the dial-in numbers for Elite Pharmaceuticals' Q1 2026 earnings call?
